<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03092375</url>
  </required_header>
  <id_info>
    <org_study_id>B16-439</org_study_id>
    <secondary_id>OCR16260</secondary_id>
    <nct_id>NCT03092375</nct_id>
  </id_info>
  <brief_title>Multi-Center, Randomized, Open-Label Study of G/P +/- RBV for NS5A + SOF Previously Treated GT1 HCV Subjects</brief_title>
  <official_title>A Phase 3b, Multi-Center, Randomized, Open-Label, Pragmatic Study of Glecaprevir/Pibrentasvir (G/P) +/- Ribavirin for GT1 Subjects With Chronic Hepatitis C Previously Treated With an NS5A Inhibitor + Sofosbuvir Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will enroll well-compensated cirrhotic as well as non-cirrhotic subjects treatment
      experienced with an NS5a Inhibitor + sofosbuvir and will include patients who did not
      complete the prescribed duration due to adverse event or any reason other than for non/poor
      compliance. Subjects will be randomized to 12 or 16 weeks of treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary purpose of this study is to compare the efficacy and safety of glecaprevir and
      pibrentasvir (G/P) for 12 weeks to G/P for 16 weeks in non-cirrhotic NS5A (non-structural
      protein 5a)-inhibitor plus sofosbuvir ± RBV (Ribavirin) treatment-experienced adults with HCV
      genotype 1 (GT1) infection, and to compare the efficacy and safety of G/P with RBV for 12
      weeks to G/P without RBV for 16 weeks in NS5A-inhibitor plus sofosbuvir (SOF) ± RBV
      treatment-experienced adults with compensated cirrhosis and GT1 infection.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 20, 2017</start_date>
  <completion_date type="Actual">February 6, 2020</completion_date>
  <primary_completion_date type="Actual">December 28, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Main Study Up to 225 subjects will be enrolled into 4 study arms A, B, C and D with Glecaprevir/Pibrentasvir (G/P) with or without Ribavirin (RBV).
About 75-90 non-cirrhotic subjects will be randomized in a 2:1 ratio to Arms A and B, and about 110-135 compensated cirrhotic subjects will be randomized in a 1:1 ratio to Arms C and D.
Non-cirrhotic subjects will be randomized 2:1 to:
Arm A: G/P 300 mg/120 mg Once a day for 12 weeks
Arm B: G/P 300 mg/120mg Once a day for 16 weeks
Subjects with compensated cirrhosis will be randomized 1:1 to:
Arm C: G/P 300 mg/120 mg QD + weight-based RBV (Ribavirin) Twice a day (1000 mg or 1200 mg total daily dose) for 12 weeks
Arm D: G/P 300 mg/120 mg QD for 16 weeks Retreatment sub-study Up to 11 subjects who still have hepatitis C virus after being treated in the Main study will have the option to enter the Retreatment sub-study and receive G/P plus Sofosbuvir and with or without RBV.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SVR After G/P 12 Wks (Arm A) vs. G/P Given for 16 Weeks (Arm B) to Non-cirrhotic Treatment-experienced GT1 HCV Participants</measure>
    <time_frame>Up to 28 weeks</time_frame>
    <description>Number of non-cirrhotic treatment-experienced HCV genotype 1 with a NS5Ai inhibitor + SOF +/-RBV participants with undetectable HCV RNA (HCV RNA &lt;Lower Limit of Quantification -LLOQ) 12 weeks after completing G/P 300 mg/100 mg daily for 12 weeks (Arm A) vs. 16 weeks of G/P 300 mg/100 mg daily (Arm B)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of Cirrhotic Participants Achieving SVR 12 After G/P Plus RBV for 12 Wks vs. G/P for 16 Wks</measure>
    <time_frame>Up to 28 weeks</time_frame>
    <description>Number of cirrhotic participants who are treatment experienced with a NS5A inhibitor + SOF +/RBV with undetectable HCV RNA 12 weeks after completing G/P plus RBV for 12 wks vs. G/P for 16 Wks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tolerability of G/P +/-RBV</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <description>Number of subjects who discontinued G/P due to adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in On-Treatment Virologic Failure Between Arms A &amp; B (Non-cirrhotic Subjects)</measure>
    <time_frame>Up to 28 weeks</time_frame>
    <description>Difference in % of subjects with on-treatment virologic failure further defined as either 1)Breakthrough a)Confirmed HCV RNA ≥ 100 IU/mL after HCV RNA &lt; Lower Limit of Quantification (LLOQ) at some point during the Treatment Period or confirmed increase from nadir in HCV RNA (two consecutive measurements &gt; 1 log10 IU/mL above nadir) at any time point during the Treatment Period, or b) a single value indicating viral breakthrough (≥ 100 IU/mL or &gt; 1 log10 above nadir), followed by patient status of 'Lost to Follow-up', the latter not requiring confirmation by a proximate measurement) or 2) End of Treatment Failure defined as HCV RNA ≥ LLOQ at end of treatment and following at least 6 weeks of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in Relapse Between Arms A &amp; B in Non-cirrhotic Subjects</measure>
    <time_frame>Up to 28 weeks</time_frame>
    <description>Difference in Post-treatment relapse (defined as confirmed HCV RNA&gt;= Lower limit of quantification (LLOQ) between end of treatment and 12 weeks after the last dose of study drug among subjects who completed treatment as planned with HCV RNA &lt; LLOQ at end of treatment, excluding subjects with subjects with reinfection)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in On-Treatment Virologic Failure Between Arms C and D in Cirrhotic Subjects</measure>
    <time_frame>Up to 28 weeks</time_frame>
    <description>Difference in percentage of cirrhotic subjects experiencing on-treatment virologic failure (confirmed increase of &gt; 1 log10 IU/mL above nadir during treatment, confirmed HCV RNA ≥ 100 IU/mL after HCV RNA &lt; 15 IU/mL during treatment, or HCV RNA ≥ LLOQ at the end of treatment with at least 6 weeks of treatment) after 12 weeks of G/P with or without RBV for 12 weeks versus 16 weeks of G/P</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in % of Relapse Between Cirrhotic Arms C &amp; D</measure>
    <time_frame>Up to 28 weeks</time_frame>
    <description>Difference in the percentage of compensated cirrhotic subjects with post-treatment relapse (defined as confirmed HCV RNA&gt;=Lower limit of quantification (LLOQ) between end of treatment and 12 weeks after last dose of study drug among subjects who completed treatment as planned with HCV RNA&lt;LLOQ at end of treatment) after receiving 12 weeks G/P +/-Ribavirin (RBV) (Arm C) versus 16 weeks G/P (Arm D)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in SVR12 Rates for 12-wk vs 16 wk</measure>
    <time_frame>28 weeks</time_frame>
    <description>Difference in proportions of SVR 12 rates will be determined for 12-week vs. 16-week treatment durations using contrasts within a logistic regression model with cirrhosis status and HCV genotype (1b vs non-1b) as factors</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">177</enrollment>
  <condition>Hepatitis C</condition>
  <condition>HCV</condition>
  <arm_group>
    <arm_group_label>Arm A: G/P 300 mg/120 mg QD for 12 Wks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Non-cirrhotic subjects will take Glecaprevir/Pibrentasvir (G/P) 300mg/120mg (3 Glecaprevir/Pibrentasvir (G/P) 100mg/40mg Tablets once-daily by mouth) for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: G/P 300 mg/120 mg QD for 16 Wks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Non-cirrhotic subjects will take Glecaprevir/Pibrentasvir (G/P) 300mg/120mg once-daily by mouth for 16 weeks (G/P 300 mg/120 mg QD for 16 Wks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C: G/P 300 mg/120 mg QD + RBV 12 Wks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cirrhotic subjects will take Glecaprevir/Pibrentasvir (G/P) 300mg/120mg once daily plus Ribavirin 200Mg Tablet (2-3 tablets) twice a day for 12 weeks (G/P 300 mg/120 mg QD + RBV 12 Wks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D: G/P 300 mg/120 mg QD for 16 Wks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cirrhotic subjects will take Glecaprevir/Pibrentasvir (G/P) 300mg/120mg once daily for 16 weeks (G/P 300 mg/120mg QD for 16 Wks)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glecaprevir/Pibrentasvir (G/P) 300mg/120mg</intervention_name>
    <description>daily</description>
    <arm_group_label>Arm A: G/P 300 mg/120 mg QD for 12 Wks</arm_group_label>
    <arm_group_label>Arm B: G/P 300 mg/120 mg QD for 16 Wks</arm_group_label>
    <arm_group_label>Arm C: G/P 300 mg/120 mg QD + RBV 12 Wks</arm_group_label>
    <arm_group_label>Arm D: G/P 300 mg/120 mg QD for 16 Wks</arm_group_label>
    <other_name>Glecaprevir/Pibrentasvir</other_name>
    <other_name>GLE/PIB (Glecaprevir/Pibrentasvir)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin 200Mg Tablet</intervention_name>
    <description>Weight-based 1000-1200 mg</description>
    <arm_group_label>Arm C: G/P 300 mg/120 mg QD + RBV 12 Wks</arm_group_label>
    <other_name>Ribasphere 200Mg Tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female at least 18 years of age at time of screening.

          2. A history of previous treatment with an NS5A-inhibitor plus sofosbuvir therapy ± RBV
             for chronic HCV genotype 1 infection.

          3. Treatment must have been completed at least 1 month prior to Screening Visit.

          4. Screening laboratory result indicating chronic HCV GT1 infection. Subjects must be
             able to understand and adhere to the study visit schedule and all other protocol
             requirements and must voluntarily sign and date an informed consent.

        Exclusion Criteria:

          1. History of severe, life-threatening or other significant sensitivity to any drug.

          2. Female who is pregnant, planning to become pregnant during the study or breastfeeding;
             or male whose partner is pregnant or planning to become pregnant during the study.

          3. Recent (within 6 months prior to study drug administration) history of drug or alcohol
             abuse that could preclude adherence to the protocol in the opinion of the
             investigator.

          4. Positive test result at Screening for hepatitis B surface antigen (HBsAg) or
             anti-human immunodeficiency virus antibody (HIV Ab) in patient without known history
             of HIV infection.

          5. HCV genotype performed during screening indicating co-infection with more than one HCV
             genotype.

          6. History or presence of liver decompensation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David R Nelson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedStar Health Research Institute</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UF Hepatology Research at CTRB</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UF Health Jacksonville-Gastroenterology Emerson</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schiff Center for Liver Diseases/University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando Immunology Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Medical Center</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>303012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Gastro Associates</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Johns Hopkins Hospital/John G. Bartlett Specialty Practice</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Digestive Disease Associates, PA</name>
      <address>
        <city>Catonsville</city>
        <state>Maryland</state>
        <zip>21228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-5601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Minnesota Health Clinics and Surgery Center, Inc.</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Therapy and Advanced Research</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwell Health - Sandra Atlaas Bass Center for Liver Diseases</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medicine, Hepatology</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Integris Baptist Medical Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania-Perelman Center for Advanced Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bon Secours Liver Institute of Virginia</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298-0341</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>March 21, 2017</study_first_submitted>
  <study_first_submitted_qc>March 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2017</study_first_posted>
  <results_first_submitted>December 18, 2019</results_first_submitted>
  <results_first_submitted_qc>January 21, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 5, 2020</results_first_posted>
  <last_update_submitted>February 17, 2020</last_update_submitted>
  <last_update_submitted_qc>February 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HCV</keyword>
  <keyword>Previously treated</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 20, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/75/NCT03092375/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 8, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/75/NCT03092375/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm A: G/P 300 mg/120 mg QD for 12 Wks</title>
          <description>Non-cirrhotic subjects will take Glecaprevir/Pibrentasvir (G/P) 300mg/120mg (3 Glecaprevir/Pibrentasvir (G/P) 100mg/40mg Tablets once-daily by mouth) for 12 weeks.
Glecaprevir/Pibrentasvir (G/P) 300mg/120mg: daily</description>
        </group>
        <group group_id="P2">
          <title>Arm B: G/P 300 mg/120 mg QD for 16 Wks</title>
          <description>Non-cirrhotic subjects will take Glecaprevir/Pibrentasvir (G/P) 300mg/120mg once-daily by mouth for 16 weeks (G/P 300 mg/120 mg QD for 16 Wks)
Glecaprevir/Pibrentasvir (G/P) 300mg/120mg: daily</description>
        </group>
        <group group_id="P3">
          <title>Arm C: G/P 300 mg/120 mg QD + RBV 12 Wks</title>
          <description>Cirrhotic subjects will take Glecaprevir/Pibrentasvir (G/P) 300mg/120mg once daily plus Ribavirin 200Mg Tablet (2-3 tablets) twice a day for 12 weeks (G/P 300 mg/120 mg QD + RBV 12 Wks)
Glecaprevir/Pibrentasvir (G/P) 300mg/120mg: daily
Ribavirin 200Mg Tablet: Weight-based 1000-1200 mg</description>
        </group>
        <group group_id="P4">
          <title>Arm D: G/P 300 mg/120 mg QD for 16 Wks</title>
          <description>Cirrhotic subjects will take Glecaprevir/Pibrentasvir (G/P) 300mg/120mg once daily for 16 weeks (G/P 300 mg/120mg QD for 16 Wks)
Glecaprevir/Pibrentasvir (G/P) 300mg/120mg: daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="78"/>
                <participants group_id="P2" count="49"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="78"/>
                <participants group_id="P2" count="48"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm A: G/P 300 mg/120 mg QD for 12 Wks</title>
          <description>Non-cirrhotic subjects will take Glecaprevir/Pibrentasvir (G/P) 300mg/120mg (3 Glecaprevir/Pibrentasvir (G/P) 100mg/40mg Tablets once-daily by mouth) for 12 weeks.
Glecaprevir/Pibrentasvir (G/P) 300mg/120mg: daily</description>
        </group>
        <group group_id="B2">
          <title>Arm B: G/P 300 mg/120 mg QD for 16 Wks</title>
          <description>Non-cirrhotic subjects will take Glecaprevir/Pibrentasvir (G/P) 300mg/120mg once-daily by mouth for 16 weeks (G/P 300 mg/120 mg QD for 16 Wks)
Glecaprevir/Pibrentasvir (G/P) 300mg/120mg: daily</description>
        </group>
        <group group_id="B3">
          <title>Arm C: G/P 300 mg/120 mg QD + RBV 12 Wks</title>
          <description>Cirrhotic subjects will take Glecaprevir/Pibrentasvir (G/P) 300mg/120mg once daily plus Ribavirin 200Mg Tablet (2-3 tablets) twice a day for 12 weeks (G/P 300 mg/120 mg QD + RBV 12 Wks)
Glecaprevir/Pibrentasvir (G/P) 300mg/120mg: daily
Ribavirin 200Mg Tablet: Weight-based 1000-1200 mg</description>
        </group>
        <group group_id="B4">
          <title>Arm D: G/P 300 mg/120 mg QD for 16 Wks</title>
          <description>Cirrhotic subjects will take Glecaprevir/Pibrentasvir (G/P) 300mg/120mg once daily for 16 weeks (G/P 300 mg/120mg QD for 16 Wks)
Glecaprevir/Pibrentasvir (G/P) 300mg/120mg: daily</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="78"/>
            <count group_id="B2" value="49"/>
            <count group_id="B3" value="21"/>
            <count group_id="B4" value="29"/>
            <count group_id="B5" value="177"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="116"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.99" lower_limit="40" upper_limit="77"/>
                    <measurement group_id="B2" value="61.37" lower_limit="45" upper_limit="75"/>
                    <measurement group_id="B3" value="59.10" lower_limit="38" upper_limit="70"/>
                    <measurement group_id="B4" value="62.59" lower_limit="42" upper_limit="81"/>
                    <measurement group_id="B5" value="61.3" lower_limit="38" upper_limit="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="23"/>
                    <measurement group_id="B5" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="77"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="96"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="29"/>
                    <measurement group_id="B5" value="180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HCV Genotype, non-1b</title>
          <description>HCV Genotype was characterized as 1b and non-1b</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="26"/>
                    <measurement group_id="B5" value="142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HCV RNA</title>
          <description>Baseline HCV RNA, log10 IU/ML, MEDIAN (RANGE)</description>
          <units>LOG10 IU/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.4" lower_limit="1.9" upper_limit="7.7"/>
                    <measurement group_id="B2" value="6.4" lower_limit="4.0" upper_limit="7.7"/>
                    <measurement group_id="B3" value="6.3" lower_limit="5.1" upper_limit="7.0"/>
                    <measurement group_id="B4" value="6.4" lower_limit="3.7" upper_limit="7.1"/>
                    <measurement group_id="B5" value="6.4" lower_limit="1.9" upper_limit="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>PLATELET</title>
          <description>Platelets collected at Baseline Lab Draw</description>
          <units>10E3 cells/uL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="204.50" lower_limit="30" upper_limit="370"/>
                    <measurement group_id="B2" value="193" lower_limit="100" upper_limit="343"/>
                    <measurement group_id="B3" value="125" lower_limit="46" upper_limit="270"/>
                    <measurement group_id="B4" value="134" lower_limit="63" upper_limit="253"/>
                    <measurement group_id="B5" value="178" lower_limit="30" upper_limit="370"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ALT</title>
          <units>u/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41" lower_limit="11" upper_limit="611"/>
                    <measurement group_id="B2" value="38" lower_limit="13" upper_limit="208"/>
                    <measurement group_id="B3" value="59" lower_limit="33" upper_limit="171"/>
                    <measurement group_id="B4" value="70" lower_limit="23" upper_limit="166"/>
                    <measurement group_id="B5" value="45" lower_limit="11" upper_limit="611"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>APRI</title>
          <description>AST to Platelet Ratio Index (APRI) (AST Level (IU/L)/AST (Upper Limit of Normal) (IU/L))/Platelet Count (109/L) * 100</description>
          <units>Index</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value=".46" lower_limit=".11" upper_limit="6.06"/>
                    <measurement group_id="B2" value=".45" lower_limit=".17" upper_limit="2.39"/>
                    <measurement group_id="B3" value="1.23" lower_limit=".41" upper_limit="6.58"/>
                    <measurement group_id="B4" value="1.47" lower_limit=".24" upper_limit="3.37"/>
                    <measurement group_id="B5" value=".57" lower_limit=".11" upper_limit="6.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Estimated GFR</title>
          <description>Estimated Glomerular Filtration Rate</description>
          <units>ml/min/1.73M2</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88.36" lower_limit="27.36" upper_limit="136.70"/>
                    <measurement group_id="B2" value="86.08" lower_limit="42.94" upper_limit="134.53"/>
                    <measurement group_id="B3" value="94.99" lower_limit="75.23" upper_limit="138.27"/>
                    <measurement group_id="B4" value="96.61" lower_limit="60.34" upper_limit="167.09"/>
                    <measurement group_id="B5" value="90.41" lower_limit="27.36" upper_limit="167.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HIV</title>
          <description>Number of patients with HIV at baseline</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Albumin</title>
          <units>g/dL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.10" lower_limit="3.20" upper_limit="4.70"/>
                    <measurement group_id="B2" value="4.10" lower_limit="2.90" upper_limit="4.60"/>
                    <measurement group_id="B3" value="4.10" lower_limit="3.20" upper_limit="4.50"/>
                    <measurement group_id="B4" value="3.90" lower_limit="3.20" upper_limit="4.50"/>
                    <measurement group_id="B5" value="4.10" lower_limit="2.90" upper_limit="4.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>SVR After G/P 12 Wks (Arm A) vs. G/P Given for 16 Weeks (Arm B) to Non-cirrhotic Treatment-experienced GT1 HCV Participants</title>
        <description>Number of non-cirrhotic treatment-experienced HCV genotype 1 with a NS5Ai inhibitor + SOF +/-RBV participants with undetectable HCV RNA (HCV RNA &lt;Lower Limit of Quantification -LLOQ) 12 weeks after completing G/P 300 mg/100 mg daily for 12 weeks (Arm A) vs. 16 weeks of G/P 300 mg/100 mg daily (Arm B)</description>
        <time_frame>Up to 28 weeks</time_frame>
        <population>These analyses were completed on Modified ITT -Genotype Population defined as all treated subjects representing their actual study regimen and who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: G/P 300 mg/120 mg QD for 12 Wks</title>
            <description>Non-cirrhotic subjects will take Glecaprevir/Pibrentasvir (G/P) 300mg/120mg (3 Glecaprevir/Pibrentasvir (G/P) 100mg/40mg Tablets once-daily by mouth) for 12 weeks.
Glecaprevir/Pibrentasvir (G/P) 300mg/120mg: daily</description>
          </group>
          <group group_id="O2">
            <title>Arm B: G/P 300 mg/120 mg QD for 16 Wks</title>
            <description>Non-cirrhotic subjects will take Glecaprevir/Pibrentasvir (G/P) 300mg/120mg once-daily by mouth for 16 weeks (G/P 300 mg/120 mg QD for 16 Wks)
Glecaprevir/Pibrentasvir (G/P) 300mg/120mg: daily</description>
          </group>
        </group_list>
        <measure>
          <title>SVR After G/P 12 Wks (Arm A) vs. G/P Given for 16 Weeks (Arm B) to Non-cirrhotic Treatment-experienced GT1 HCV Participants</title>
          <description>Number of non-cirrhotic treatment-experienced HCV genotype 1 with a NS5Ai inhibitor + SOF +/-RBV participants with undetectable HCV RNA (HCV RNA &lt;Lower Limit of Quantification -LLOQ) 12 weeks after completing G/P 300 mg/100 mg daily for 12 weeks (Arm A) vs. 16 weeks of G/P 300 mg/100 mg daily (Arm B)</description>
          <population>These analyses were completed on Modified ITT -Genotype Population defined as all treated subjects representing their actual study regimen and who received at least one dose of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Virologic Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Virologic Failure</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Comparison of Cirrhotic Participants Achieving SVR 12 After G/P Plus RBV for 12 Wks vs. G/P for 16 Wks</title>
        <description>Number of cirrhotic participants who are treatment experienced with a NS5A inhibitor + SOF +/RBV with undetectable HCV RNA 12 weeks after completing G/P plus RBV for 12 wks vs. G/P for 16 Wks</description>
        <time_frame>Up to 28 weeks</time_frame>
        <population>Cirrhotic subjects achieving Virologic Response at Post-Treatment Week 12</population>
        <group_list>
          <group group_id="O1">
            <title>Arm C: G/P 300 mg/120 mg QD + RBV 12 Wks</title>
            <description>Cirrhotic subjects will take Glecaprevir/Pibrentasvir (G/P) 300mg/120mg once daily plus Ribavirin 200Mg Tablet (2-3 tablets) twice a day for 12 weeks (G/P 300 mg/120 mg QD + RBV 12 Wks)
Glecaprevir/Pibrentasvir (G/P) 300mg/120mg: daily
Ribavirin 200Mg Tablet: Weight-based 1000-1200 mg</description>
          </group>
          <group group_id="O2">
            <title>Arm D: G/P 300 mg/120 mg QD for 16 Wks</title>
            <description>Arm D includes Cirrhotic subjects receiving Glecaprevir/Pibrentasvir (G/P) 300mg/120mg once daily for 16 weeks (G/P 300 mg/120mg QD for 16 Wks)
Glecaprevir/Pibrentasvir (G/P) 300mg/120mg: daily</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Cirrhotic Participants Achieving SVR 12 After G/P Plus RBV for 12 Wks vs. G/P for 16 Wks</title>
          <description>Number of cirrhotic participants who are treatment experienced with a NS5A inhibitor + SOF +/RBV with undetectable HCV RNA 12 weeks after completing G/P plus RBV for 12 wks vs. G/P for 16 Wks</description>
          <population>Cirrhotic subjects achieving Virologic Response at Post-Treatment Week 12</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Virologic Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Virologic Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tolerability of G/P +/-RBV</title>
        <description>Number of subjects who discontinued G/P due to adverse events</description>
        <time_frame>Up to 16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm A: G/P 300 mg/120 mg QD for 12 Wks</title>
            <description>Non-cirrhotic subjects will take Glecaprevir/Pibrentasvir (G/P) 300mg/120mg (3 Glecaprevir/Pibrentasvir (G/P) 100mg/40mg Tablets once-daily by mouth) for 12 weeks.
Glecaprevir/Pibrentasvir (G/P) 300mg/120mg: daily</description>
          </group>
          <group group_id="O2">
            <title>Arm B: G/P 300 mg/120 mg QD for 16 Wks</title>
            <description>Non-cirrhotic subjects will take Glecaprevir/Pibrentasvir (G/P) 300mg/120mg once-daily by mouth for 16 weeks (G/P 300 mg/120 mg QD for 16 Wks)
Glecaprevir/Pibrentasvir (G/P) 300mg/120mg: daily</description>
          </group>
          <group group_id="O3">
            <title>Arm C: G/P 300 mg/120 mg QD + RBV 12 Wks</title>
            <description>Cirrhotic subjects will take Glecaprevir/Pibrentasvir (G/P) 300mg/120mg once daily plus Ribavirin 200Mg Tablet (2-3 tablets) twice a day for 12 weeks (G/P 300 mg/120 mg QD + RBV 12 Wks)
Glecaprevir/Pibrentasvir (G/P) 300mg/120mg: daily
Ribavirin 200Mg Tablet: Weight-based 1000-1200 mg</description>
          </group>
          <group group_id="O4">
            <title>Arm D: G/P 300 mg/120 mg QD for 16 Wks</title>
            <description>Cirrhotic subjects will take Glecaprevir/Pibrentasvir (G/P) 300mg/120mg once daily for 16 weeks (G/P 300 mg/120mg QD for 16 Wks)
Glecaprevir/Pibrentasvir (G/P) 300mg/120mg: daily</description>
          </group>
        </group_list>
        <measure>
          <title>Tolerability of G/P +/-RBV</title>
          <description>Number of subjects who discontinued G/P due to adverse events</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference in On-Treatment Virologic Failure Between Arms A &amp; B (Non-cirrhotic Subjects)</title>
        <description>Difference in % of subjects with on-treatment virologic failure further defined as either 1)Breakthrough a)Confirmed HCV RNA ≥ 100 IU/mL after HCV RNA &lt; Lower Limit of Quantification (LLOQ) at some point during the Treatment Period or confirmed increase from nadir in HCV RNA (two consecutive measurements &gt; 1 log10 IU/mL above nadir) at any time point during the Treatment Period, or b) a single value indicating viral breakthrough (≥ 100 IU/mL or &gt; 1 log10 above nadir), followed by patient status of 'Lost to Follow-up', the latter not requiring confirmation by a proximate measurement) or 2) End of Treatment Failure defined as HCV RNA ≥ LLOQ at end of treatment and following at least 6 weeks of treatment.</description>
        <time_frame>Up to 28 weeks</time_frame>
        <population>Analysis was performed the study population &quot;as treated&quot; further defined as mITT-all subjects representing their actual study regimen and who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Arms A G/P 300 mg/120 mg QD for 12 Weeks</title>
            <description>Arms A includes non-cirrhotic subjects receiving Glecaprevir/Pibrentasvir (G/P) 300mg/120mg once-daily by mouth with or without Ribavirin for 12 weeks (Arm A) Glecaprevir/Pibrentasvir (G/P) 300mg/120mg: daily</description>
          </group>
          <group group_id="O2">
            <title>Arm B G/P 300/120mg Once Daily for 16 Weeks</title>
            <description>Arm B includes non-cirrhotic subjects receiving Glecaprevir/Pibrentasvir (G/P) 300mg/120mg once-daily by mouth for 16 weeks (G/P 300 mg/120 mg QD for 16 Wks)
Glecaprevir/Pibrentasvir (G/P) 300mg/120mg: daily</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in On-Treatment Virologic Failure Between Arms A &amp; B (Non-cirrhotic Subjects)</title>
          <description>Difference in % of subjects with on-treatment virologic failure further defined as either 1)Breakthrough a)Confirmed HCV RNA ≥ 100 IU/mL after HCV RNA &lt; Lower Limit of Quantification (LLOQ) at some point during the Treatment Period or confirmed increase from nadir in HCV RNA (two consecutive measurements &gt; 1 log10 IU/mL above nadir) at any time point during the Treatment Period, or b) a single value indicating viral breakthrough (≥ 100 IU/mL or &gt; 1 log10 above nadir), followed by patient status of 'Lost to Follow-up', the latter not requiring confirmation by a proximate measurement) or 2) End of Treatment Failure defined as HCV RNA ≥ LLOQ at end of treatment and following at least 6 weeks of treatment.</description>
          <population>Analysis was performed the study population &quot;as treated&quot; further defined as mITT-all subjects representing their actual study regimen and who received at least one dose of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The difference in the percentage of subjects with on-treatment virologic failure (Defined as increase of &gt;1 log10 IU/mL above nadir during treatment, or HCV RNA &gt;= 15 IU/mL at end of treatment with at least 6 weeks of treatment between Arms A and B are summarized with two-sided 95% Wilson score intervals.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Study is not intended to be powered</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.48</ci_lower_limit>
            <ci_upper_limit>5.12</ci_upper_limit>
            <estimate_desc>Excludes re-infection and death</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference in Relapse Between Arms A &amp; B in Non-cirrhotic Subjects</title>
        <description>Difference in Post-treatment relapse (defined as confirmed HCV RNA&gt;= Lower limit of quantification (LLOQ) between end of treatment and 12 weeks after the last dose of study drug among subjects who completed treatment as planned with HCV RNA &lt; LLOQ at end of treatment, excluding subjects with subjects with reinfection)</description>
        <time_frame>Up to 28 weeks</time_frame>
        <population>Analysis performed on any subject with study drug duration of 77 days or greater for Arm A or 105 days or greater for Arm B</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: G/P 300 mg/120 mg QD for 12 Wks</title>
            <description>Non-cirrhotic subjects receiving Glecaprevir/Pibrentasvir (G/P) 300mg/120mg (3 Glecaprevir/Pibrentasvir (G/P) 100mg/40mg Tablets once-daily by mouth) for 12 weeks.
Glecaprevir/Pibrentasvir (G/P) 300mg/120mg: daily</description>
          </group>
          <group group_id="O2">
            <title>Arm B: G/P 300 mg/120 mg QD for 16 Wks</title>
            <description>Non-cirrhotic subjects will take Glecaprevir/Pibrentasvir (G/P) 300mg/120mg once-daily by mouth for 16 weeks (G/P 300 mg/120 mg QD for 16 Wks)
Glecaprevir/Pibrentasvir (G/P) 300mg/120mg: daily</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in Relapse Between Arms A &amp; B in Non-cirrhotic Subjects</title>
          <description>Difference in Post-treatment relapse (defined as confirmed HCV RNA&gt;= Lower limit of quantification (LLOQ) between end of treatment and 12 weeks after the last dose of study drug among subjects who completed treatment as planned with HCV RNA &lt; LLOQ at end of treatment, excluding subjects with subjects with reinfection)</description>
          <population>Analysis performed on any subject with study drug duration of 77 days or greater for Arm A or 105 days or greater for Arm B</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The difference in the percentage of subjects with post-treatment relapse between Arms A and B are summarized with two-sided 95% Wilson score intervals.</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.49</ci_lower_limit>
            <ci_upper_limit>5.49</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference in On-Treatment Virologic Failure Between Arms C and D in Cirrhotic Subjects</title>
        <description>Difference in percentage of cirrhotic subjects experiencing on-treatment virologic failure (confirmed increase of &gt; 1 log10 IU/mL above nadir during treatment, confirmed HCV RNA ≥ 100 IU/mL after HCV RNA &lt; 15 IU/mL during treatment, or HCV RNA ≥ LLOQ at the end of treatment with at least 6 weeks of treatment) after 12 weeks of G/P with or without RBV for 12 weeks versus 16 weeks of G/P</description>
        <time_frame>Up to 28 weeks</time_frame>
        <population>Analysis was performed the study population &quot;as treated&quot; further defined as mITT-all subjects representing their actual study regimen and who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm C: G/P 300 mg/120 mg QD + RBV 12 Wks</title>
            <description>Cirrhotic subjects will take Glecaprevir/Pibrentasvir (G/P) 300mg/120mg once daily plus Ribavirin 200Mg Tablet (2-3 tablets) twice a day for 12 weeks (G/P 300 mg/120 mg QD + RBV 12 Wks)
Glecaprevir/Pibrentasvir (G/P) 300mg/120mg: daily
Ribavirin 200Mg Tablet: Weight-based 1000-1200 mg</description>
          </group>
          <group group_id="O2">
            <title>Arm D: G/P 300 mg/120 mg QD for 16 Wks</title>
            <description>Cirrhotic subjects receiving Glecaprevir/Pibrentasvir (G/P) 300mg/120mg once daily for 16 weeks (G/P 300 mg/120mg QD for 16 Wks)
Glecaprevir/Pibrentasvir (G/P) 300mg/120mg: daily</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in On-Treatment Virologic Failure Between Arms C and D in Cirrhotic Subjects</title>
          <description>Difference in percentage of cirrhotic subjects experiencing on-treatment virologic failure (confirmed increase of &gt; 1 log10 IU/mL above nadir during treatment, confirmed HCV RNA ≥ 100 IU/mL after HCV RNA &lt; 15 IU/mL during treatment, or HCV RNA ≥ LLOQ at the end of treatment with at least 6 weeks of treatment) after 12 weeks of G/P with or without RBV for 12 weeks versus 16 weeks of G/P</description>
          <population>Analysis was performed the study population &quot;as treated&quot; further defined as mITT-all subjects representing their actual study regimen and who received at least one dose of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Difference in percentage of subjects with on-treatment virologic failure between Arms C and D will be summarized with two-sided 95% Wilson score intervals</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>9.52</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.03</ci_lower_limit>
            <ci_upper_limit>22.08</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference in % of Relapse Between Cirrhotic Arms C &amp; D</title>
        <description>Difference in the percentage of compensated cirrhotic subjects with post-treatment relapse (defined as confirmed HCV RNA&gt;=Lower limit of quantification (LLOQ) between end of treatment and 12 weeks after last dose of study drug among subjects who completed treatment as planned with HCV RNA&lt;LLOQ at end of treatment) after receiving 12 weeks G/P +/-Ribavirin (RBV) (Arm C) versus 16 weeks G/P (Arm D)</description>
        <time_frame>Up to 28 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm C: G/P 300 mg/120 mg QD + RBV 12 Wks</title>
            <description>Cirrhotic subjects will take Glecaprevir/Pibrentasvir (G/P) 300mg/120mg once daily plus Ribavirin 200Mg Tablet (2-3 tablets) twice a day for 12 weeks (G/P 300 mg/120 mg QD + RBV 12 Wks)
Glecaprevir/Pibrentasvir (G/P) 300mg/120mg: daily
Ribavirin 200Mg Tablet: Weight-based 1000-1200 mg</description>
          </group>
          <group group_id="O2">
            <title>Arm D: G/P 300 mg/120 mg QD for 16 Wks</title>
            <description>Cirrhotic subjects will take Glecaprevir/Pibrentasvir (G/P) 300mg/120mg once daily for 16 weeks (G/P 300 mg/120mg QD for 16 Wks)
Glecaprevir/Pibrentasvir (G/P) 300mg/120mg: daily</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in % of Relapse Between Cirrhotic Arms C &amp; D</title>
          <description>Difference in the percentage of compensated cirrhotic subjects with post-treatment relapse (defined as confirmed HCV RNA&gt;=Lower limit of quantification (LLOQ) between end of treatment and 12 weeks after last dose of study drug among subjects who completed treatment as planned with HCV RNA&lt;LLOQ at end of treatment) after receiving 12 weeks G/P +/-Ribavirin (RBV) (Arm C) versus 16 weeks G/P (Arm D)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Excludes re-infection and death</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.85</ci_lower_limit>
            <ci_upper_limit>10.22</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference in SVR12 Rates for 12-wk vs 16 wk</title>
        <description>Difference in proportions of SVR 12 rates will be determined for 12-week vs. 16-week treatment durations using contrasts within a logistic regression model with cirrhosis status and HCV genotype (1b vs non-1b) as factors</description>
        <time_frame>28 weeks</time_frame>
        <population>Modified Intent to Treat Population (mITT) analysis (All subjects enroll in Main study receiving at least one dose of study drug and according to the treatment arm in which they were actually treated)</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: G/P 300 mg/120 mg QD for 12 Wks</title>
            <description>Non-cirrhotic subjects will take Glecaprevir/Pibrentasvir (G/P) 300mg/120mg (3 Glecaprevir/Pibrentasvir (G/P) 100mg/40mg Tablets once-daily by mouth) for 12 weeks.
Glecaprevir/Pibrentasvir (G/P) 300mg/120mg: daily</description>
          </group>
          <group group_id="O2">
            <title>Arm B: G/P 300 mg/120 mg QD for 16 Wks</title>
            <description>Non-cirrhotic subjects will take Glecaprevir/Pibrentasvir (G/P) 300mg/120mg once-daily by mouth for 16 weeks (G/P 300 mg/120 mg QD for 16 Wks)
Glecaprevir/Pibrentasvir (G/P) 300mg/120mg: daily</description>
          </group>
          <group group_id="O3">
            <title>Arm C: G/P 300 mg/120 mg QD + RBV 12 Wks</title>
            <description>Cirrhotic subjects will take Glecaprevir/Pibrentasvir (G/P) 300mg/120mg once daily plus Ribavirin 200Mg Tablet (2-3 tablets) twice a day for 12 weeks (G/P 300 mg/120 mg QD + RBV 12 Wks)
Glecaprevir/Pibrentasvir (G/P) 300mg/120mg: daily
Ribavirin 200Mg Tablet: Weight-based 1000-1200 mg</description>
          </group>
          <group group_id="O4">
            <title>Arm D: G/P 300 mg/120 mg QD for 16 Wks</title>
            <description>Cirrhotic subjects will take Glecaprevir/Pibrentasvir (G/P) 300mg/120mg once daily for 16 weeks (G/P 300 mg/120mg QD for 16 Wks)
Glecaprevir/Pibrentasvir (G/P) 300mg/120mg: daily</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in SVR12 Rates for 12-wk vs 16 wk</title>
          <description>Difference in proportions of SVR 12 rates will be determined for 12-week vs. 16-week treatment durations using contrasts within a logistic regression model with cirrhosis status and HCV genotype (1b vs non-1b) as factors</description>
          <population>Modified Intent to Treat Population (mITT) analysis (All subjects enroll in Main study receiving at least one dose of study drug and according to the treatment arm in which they were actually treated)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Study was not powered to compare efficacy</non_inferiority_desc>
            <p_value>0.161</p_value>
            <method>Chi-squared</method>
            <method_desc>Logistic regression contrast estimates with Wald confidence intervals and Chi-square p values</method_desc>
            <param_type>Logistic Regression Contrast Estimate</param_type>
            <param_value>-0.812</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.947</ci_lower_limit>
            <ci_upper_limit>0.323</ci_upper_limit>
            <estimate_desc>Comparison of Arm Pair A/C versus B/D overall on mITT population</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Study is not powered to compare efficacy of 12 wks vs 16 weeks of treatment</non_inferiority_desc>
            <p_value>0.890</p_value>
            <method>Chi-squared</method>
            <method_desc>Logistic regression contrast estimates with Wald confidence intervals and Chi-square p values</method_desc>
            <param_type>Logistic regression contrast estimate</param_type>
            <param_value>0.890</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.239</ci_lower_limit>
            <ci_upper_limit>1.076</ci_upper_limit>
            <estimate_desc>Difference in proportion of SVR12 rates for 12 vs 16 weeks on mITT Comparing Cirrhotic subjects versus non-cirrhotic subjects.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison of 12 weeks vs 16 weeks in Genotype 1b vs non-1b</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Study is not powered</non_inferiority_desc>
            <p_value>0.265</p_value>
            <method>Chi-squared</method>
            <param_type>Logistic regression contrast estimate</param_type>
            <param_value>0.977</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.740</ci_lower_limit>
            <ci_upper_limit>2.694</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>142 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Arm A: G/P 300 mg/120 mg QD for 12 Wks</title>
          <description>Non-cirrhotic subjects will take Glecaprevir/Pibrentasvir (G/P) 300mg/120mg (3 Glecaprevir/Pibrentasvir (G/P) 100mg/40mg Tablets once-daily by mouth) for 12 weeks.
Glecaprevir/Pibrentasvir (G/P) 300mg/120mg: daily</description>
        </group>
        <group group_id="E2">
          <title>Arm B: G/P 300 mg/120 mg QD for 16 Wks</title>
          <description>Non-cirrhotic subjects will take Glecaprevir/Pibrentasvir (G/P) 300mg/120mg once-daily by mouth for 16 weeks (G/P 300 mg/120 mg QD for 16 Wks)
Glecaprevir/Pibrentasvir (G/P) 300mg/120mg: daily</description>
        </group>
        <group group_id="E3">
          <title>Arm C: G/P 300 mg/120 mg QD + RBV 12 Wks</title>
          <description>Cirrhotic subjects will take Glecaprevir/Pibrentasvir (G/P) 300mg/120mg once daily plus Ribavirin 200Mg Tablet (2-3 tablets) twice a day for 12 weeks (G/P 300 mg/120 mg QD + RBV 12 Wks)
Glecaprevir/Pibrentasvir (G/P) 300mg/120mg: daily
Ribavirin 200Mg Tablet: Weight-based 1000-1200 mg</description>
        </group>
        <group group_id="E4">
          <title>Arm D: G/P 300 mg/120 mg QD for 16 Wks</title>
          <description>Cirrhotic subjects will take Glecaprevir/Pibrentasvir (G/P) 300mg/120mg once daily for 16 weeks (G/P 300 mg/120mg QD for 16 Wks)
Glecaprevir/Pibrentasvir (G/P) 300mg/120mg: daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (15.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Small Intestinal Obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Hepatocellular Carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>HCC final outcome Death</sub_title>
                <description>Death related to HCC</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic Obstruction Pulmonary Disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (15.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="78"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="49"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="78"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="49"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="21"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="17" subjects_affected="15" subjects_at_risk="78"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="49"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="21"/>
                <counts group_id="E4" events="7" subjects_affected="6" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This study did not include a group that received 16 weeks of glecaprevir and pibrentasvir with ribavirin.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Lauren Morelli</name_or_title>
      <organization>UF Hepatology Research at CTRB</organization>
      <phone>3522739508</phone>
      <email>LAUREN.MORELLI@MEDICINE.UFL.EDU</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

